Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01717391 · ClinicalTrials.gov registry record · Phase 2
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
A Phase 2 study, sponsored by John M. Buatti.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01717391 is a Phase 2 study that has completed, run by John M. Buatti. The registered enrollment target is 36 participants.
The verdict
NCT01717391, a Phase 2 study, has completed, sponsored by John M. Buatti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
\[F-18\] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.
Interventions
- DRUG fluorothymidine F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2017-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01717391
The ClinicalTrials.gov registry entry for NCT01717391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John M. Buatti, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluorothymidine F 18 is the first listed.
NCT01717391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01717391 about?
NCT01717391 is a clinical study titled "[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers". \[F-18\] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.
What is the current status of trial NCT01717391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2012-10-01. Estimated completion is 2017-04-30.
What interventions are being tested in trial NCT01717391?
The interventions under investigation include: fluorothymidine F 18 (DRUG).
Who is sponsoring clinical trial NCT01717391?
This trial is sponsored by John M. Buatti, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.